Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials

Schizophrenia Bulletin

Volumn 40, Issue 1, 2014, Pages 192-213

  Kishimoto, Taishiro ^a,b   Robenzadeh, Alfred ^a   Leucht, Claudia ^c   Leucht, Stefan ^c   Watanabe, Koichiro ^b,d   Mimura, Masaru ^b   Borenstein, Michael ^e   Kane, John M ^a,f,g,h   Correll, Christoph U ^a,f,g,h  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Biostat Inc   (United States)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

adherence; antipsychotics; depot; long acting injection; meta analysis; relapse; schizophrenia; treatment discontinuation

Indexed keywords

FLUPHENAZINE; NEUROLEPTIC AGENT;

ARTICLE; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RELAPSE; SCHIZOPHRENIA; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADHERENCE; ANTIPSYCHOTICS; DEPOT; LONG-ACTING INJECTION; META-ANALYSIS; RELAPSE; SCHIZOPHRENIA; TREATMENT DISCONTINUATION;

ANTIPSYCHOTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SCHIZOPHRENIA;

EID: 84892639627     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbs150     Document Type: Article

References (53)

1. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001;50:884-897.
2. van Haren NE, Hulshoff Pol HE, Schnack HG, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology. 2007;32:2057-2066.
3. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247.
4. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory metaanalysis of randomized, controlled trials. Am J Psychiatry. 2003;160:1209-1222.
5. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14:429-447.
6. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379: 2063-2071.
7. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents Am J Psychiatry. 2002;159:103-108.
8. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007;58:1187-1192.
9. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S63-S67.
10. Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl. 2009;52:S43-S50.
11. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127:83-92.
12. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364:842-851.
13. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167:181-189.
14. Macfadden W, Ma YW, Thomas Haskins J, Bossie CA, Alphs L. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry. 2010;7:23-31.
15. Schooler NR, Buckley PF, Mintz J, et al. PROACTIVE: initial results of an RCT comparing long-acting injectable risperidone to 2nd generation oral antipsychotics. American College of Neuropsychopharmacology 50th annual meeting. Kona, Hawaii; 2011.
16. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ. 2009;339:b2535.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
18. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1-56.
19. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663-667.
20. Foster P. Neuroleptic equivalence. Pharmaceut J. 1989;243: 431-432.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
22. Li R, Zhang M, Shi S. The effect of haloperidol decanoate on negative and positive symptoms of schizophrenia. Chin J Nerv Mental Dis. 1996;22:9-12.
23. Bai YM, Chen TT, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry. 2007;68:1218-1225.
24. Arango C, Bomb I, Gonzez-Salvador T, Garc-Cabeza I, Bobes J. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiatry. 2006;21:34-40.
25. del Giudice J, Clark WG, Gocka EF. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics. 1975;16:32-36.
26. Falloon I, Watt DC, Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med. 1978;8:59-70.
27. Rifkin A, Quitkin F, Rabiner CJ, Klein DF. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Arch Gen Psychiatry. 1977;34:43-47.
28. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
29. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics [published online ahead of print November 29, 2011]. Mol Psychiatry. doi:10.1038/mp.2011.143.
30. Tiihonen J, Wahlbeck K, Lnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333:224.
31. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603-609.
32. Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. Does longacting injectable risperidone make a difference to the reallife treatment of schizophrenia Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res. 2012;134:187-194.
33. Lambert T, Olivares JM, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry. 2011;10:10.
34. Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res. 2011;3:9-14.
35. Haddad PM, Tiihonen J, Haukka J, Taylor M, Patel MX, Korhonen P. The place of observational studies in assessing the effectiveness of depot antipsychotics. Schizophr Res. 2011;131:260-261.
36. Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci. 2011;13:155-172.
37. A study of the efficacy and safety of long-acting injectible risperidone and risperidone tablets in patients with schizophrenia; Clinical Trials.gov Identifier NCT00240708. http://filehosting.pharmacm.com/DownloadService. ashxclient=CTR-JNJ-6051&studyid=409&filename=CR00 4945-CSR.pdf. Accessed March 1, 2012.
38. Kamijima K, Ishigooka J, Komada Y. Comparison study between risperidone long-acting injectable and risperidone tablets in patients with schizophrenia. Jpn J Clin Psychopharmacol. 2009;12:1199-1222.
39. Silvestri S, Seeman MV, Negrete JC, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology. 2000;152:174-180.
40. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. " Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27:2979-2986.
41. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry. 2008;64:145-152.
42. Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebocontrolled trial. J Clin Psychiatry. 2011;72:1042-1048.
43. Schooler NR, Levine J, Severe JB, et al. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Arch Gen Psychiatry. 1980;37:16-24.
44. An open-label randomized trial comparing Risperdal* Consta* with oral antipsychotic care in the treatment of early psychosis; Clinical Trials.gov Identifier NCT00246259. http://download. veritasmedicine.com/PDF/ CR005959-CSR-synopsis.pdf. Accessed March 1, 2012.
45. Crawford R, Forrest A. Controlled trial of depot fluphenazine in out-patient schizophrenics. Br J Psychiatry. 1974;124:385-391.
46. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry. 1979;36:1283-1294.
47. Barnes TR, Milavic G, Curson DA, Platt SD. Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: pimozide versus fluphenazine. Soc Psychiatry. 1983;18:193-199.
48. Kaneno S, Ohkuma T, Yamashita I, et al. A double blind comparative study on the efficacy and safety of fluphenazine decanoate (SQ10, 733) and oral haloperidol in the treatment of schizophrenic patients. Rinsho Hyoka (clinical evaluation). 1991;19:15-45.
49. Glick ID, Marder SR. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005;66:638-641.
50. Detke HC, Weiden PJ, Llorca P-M, Choukour M, Watson SB, Brunner E, Ascher-Svanum H. Open-label comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized study in outpatients with schizophrenia. NCDEU 51st annual meeting. Boca Raton, FL; 2011.
51. Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, openlabel study. Br J Psychiatry. 2007;191:131-139.
52. Potapov A, Eduard T, Sergey M. Response, remission and relapse during the long-term treatment of schizophrenia patients with long-acting injectable risperidone versus olanzapine. Int J Neuropsychopharmacol. 2008;11:158-158.
53. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35:2367-2377.